Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Advanced NSCLC Patients
NCT04250545Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2020
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of telaglenastat and sapanisertib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose/Recommended Phase II Dose at 28 days, Overall Response Rate at 27 months and 1 more. Started Oct 2020; status: active, not recruiting.
02
Drugs
telaglenastatsapanisertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04250545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250545.